| abstract |
The preemptive or early administration of the toxic targeting agent provides a method for preventing or ameliorating the toxicity caused by or due to therapy such as immunotherapy or cell therapy. In some embodiments, the therapy is a cell therapy and the cells are generally recombinant receptors, eg, chimeric receptors, eg, chimeric antigen receptors (CAR), or other transgenic receptors, eg, T It expresses a cellular receptor (TCR). The features of the method, including the timing of administration of the active agent or treatment for toxicity provide various advantages such as lower toxicity while maintaining the persistence and potency of the administered cells. |